This article first appeared on GuruFocus.

Humacyte Inc (NASDAQ:HUMA) is set to release its Q3 2025 earnings on Nov 12, 2025. The consensus estimate for Q3 2025 revenue is $0.92 million, and the earnings are expected to come in at -$0.16 per share. The full year 2025's revenue is expected to be $3.64 million and the earnings are expected to be -$0.30 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 5 Warning Signs with HUMA.

Is HUMA fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Humacyte Inc (NASDAQ:HUMA) have declined from $7.78 million to $3.64 million for the full year 2025 and declined from $80.60 million to $57.02 million for 2026 over the past 90 days. Earnings estimates have declined from -$0.19 per share to -$0.30 per share for the full year 2025 and declined from -$0.25 per share to -$0.29 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Humacyte Inc's (NASDAQ:HUMA) actual revenue was $0.30 million, which missed analysts' revenue expectations of $1.00 million by -69.99%. Humacyte Inc's (NASDAQ:HUMA) actual earnings were -$0.24 per share, which missed analysts' earnings expectations of -$0.16 per share by -48.15%. After releasing the results, Humacyte Inc (NASDAQ:HUMA) was down by -29.64% in one day.

Based on the one-year price targets offered by 7 analysts, the average target price for Humacyte Inc (NASDAQ:HUMA) is $8.29 with a high estimate of $25.00 and a low estimate of $3.00. The average target implies an upside of 516.04% from the current price of $1.35.

Based on GuruFocus estimates, the estimated GF Value for Humacyte Inc (NASDAQ:HUMA) in one year is $0, suggesting a downside of -100% from the current price of $1.35.

Based on the consensus recommendation from 7 brokerage firms, Humacyte Inc's (NASDAQ:HUMA) average brokerage recommendation is currently 2.0, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.